Media coverage about Halozyme Therapeutics (NASDAQ:HALO) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.8061236661652 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern’s analysis:

Halozyme Therapeutics (HALO) traded down 1.57% on Wednesday, reaching $12.53. The company’s stock had a trading volume of 203,068 shares. The company’s market capitalization is $1.68 billion. Halozyme Therapeutics has a 1-year low of $8.18 and a 1-year high of $15.20. The stock has a 50 day moving average price of $12.72 and a 200-day moving average price of $13.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $33.80 million during the quarter, compared to the consensus estimate of $31.76 million. The business’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the business earned ($0.21) EPS. Equities analysts predict that Halozyme Therapeutics will post ($0.97) earnings per share for the current fiscal year.

A number of brokerages recently weighed in on HALO. BidaskClub upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Friday, August 25th. Piper Jaffray Companies set a $20.00 price objective on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 10th. Jefferies Group LLC reissued an “underperform” rating and issued a $7.00 price objective (up from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Finally, Canaccord Genuity set a $16.00 price objective on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $14.75.

WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.